Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02254239 (Clinical Trial/ Brentuximab vedotin)

Study Title
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT02254239)

Trial Description
This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. 

Brentuximab vedotin (also known as SGN-035) may interfere with the ability of cancer cells to grow and spread by binding to a protein on the surface of cancer cells and then releasing a cancer-killing substance to them. Giving everolimus together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.

This trial is sponsored by Mayo Clinic/ National Cancer Institute (NCI) [1]

Study Data

  • Condition: Lymphoma
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 26
  • Start: September 2015
  • Estimated Primary Completion: September 2020 (Final data collection date for primary outcome measure)
  • Last verified: June 2015

Study Schematic 

Screen Shot 2016-07-11 at 10.38.10 AM


Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar